DRUG INDUSTRY-Redesigning Strategies

Redesigning Strategies WITH the National Pharmaceutical Pricing Authority (NPPA) finally setting up shop, it is not surprising that the first major issue it has had to consider is the five-point charter of the Organisation of Pharmaceutical Producers of India, comprising overwhelmingly MNCs and their subsidiaries, seeking a review of pricing policy. The demands are that (I) prices should be based on actual and not normative costs, (2) inflationary increases in input costs must be covered, (3) costs of utilities as fixed by the government must not be converted into cheaper prices and (4) the pricing formula should reflect the value of medicines.